We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.


SEKISUI XenoTech Announces Enhanced Synergy in ADME Testing Services

SEKISUI XenoTech Announces Enhanced Synergy in ADME Testing Services content piece image
Image credit: SEKISUI XenoTech
Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: 1 minute
SEKISUI XenoTech is collaborating with the Drug Development Solutions Center to offer a full suite of nonclinical testing services specializing in the evaluation of Absorption, Distribution, Metabolism, and Excretion (ADME) in potential new drugs.

For nearly 25 years SEKISUI XenoTech has been highly regarded for its extensive selection of drug metabolism-focused test systems and in vitro services investigating drug metabolism and drug-drug interactions in support of safety and risk mitigation for drug developers. Now with support from the Drug Development Solutions Center of the SEKISUI Medical Group, a wide range of studies is provided to thoroughly evaluate biotransformation and the potential journey of a prospective drug candidate compound when taken by a patient.

Satoshi Ito, Manager of the Business Planning and Development Department of the Drug Development Solutions Division of SEKISUI Medical, said, “Bringing together the 64 years of in vivo studies and radiolabeling expertise with the exceptional in vitro capabilities of XenoTech creates a partnership that can serve drug developers and ultimately patients worldwide in a wider and more robust capacity than ever before.”

Services offered by the Drug Development Solutions Center include in vivo ADME studies, with specialties in Quantitative Whole Body Autoradiography (QWBA), Metabolite Identification, Mass Balance and Tissue Dissection. These studies utilize highly specialized skills and a deep well of knowledge and experience in radioisotope (RI) labeling technology.

“I am excited to offer these in vivo studies that help to complete our large and comprehensive portfolio of ADME services, which help drug developers to efficiently move effective, safe therapeutics through the pipeline to market where patients can benefit,” stated Dr. Darren Warren, COO of SEKISUI XenoTech.

A recent blog post on the SEKISUI XenoTech website gives a more detailed look into the history and development of both companies and their partnership.